{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:38:05Z","timestamp":1770817085266,"version":"3.50.1"},"reference-count":28,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with active ankylosing spondylitis (AS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This phase III, multicenter, double-blind, placebo-controlled study (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01583374\">NCT01583374<\/jats:ext-link>) randomized patients with active AS (1:1:1) to placebo, apremilast 20 mg twice daily, or apremilast 30 mg twice daily for 24 weeks, followed by a long-term extension phase (up to 5 yrs). The primary endpoint was Assessment of the Spondyloarthritis international Society 20 (ASAS20) response at Week 16. The effect of treatment on radiographic outcomes after 104 weeks was assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 490 patients with active AS were randomized in the study (placebo: n = 164; apremilast 20 mg twice daily: n = 163; apremilast 30 mg twice daily: n = 163). The primary endpoint of ASAS20 response at Week 16 was not met (placebo: 37%; apremilast 20 mg twice daily: 35%; apremilast 30 mg twice daily: 33%; <jats:italic>P<\/jats:italic> = 0.44 vs placebo). At Week 104, mean (SD) changes from baseline in mSASSS were 0.83 (3.6), 0.98 (2.2), and 0.57 (1.9) in patients initially randomized to placebo, apremilast 20 mg twice daily, and apremilast 30 mg twice daily, respectively. The most frequently reported adverse events through Week 104 were diarrhea, nasopharyngitis, upper respiratory infection, and nausea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>No clinical benefit was observed with apremilast treatment in patients with active AS. The safety and tolerability of apremilast were consistent with its known profile.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.201088","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T13:53:02Z","timestamp":1613397182000},"page":"1259-1267","source":"Crossref","is-referenced-by-count":12,"title":["A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"McCue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-9533","authenticated-orcid":false,"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"2022062114102984000_48.8.1259.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406182"},{"key":"2022062114102984000_48.8.1259.2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4329\/wjr.v7.i9.236","article-title":"Ankylosing spondylitis: a state of the art factual backbone","volume":"7","author":"Ghasemi-Rad","year":"2015","journal-title":"World J Radiol"},{"key":"2022062114102984000_48.8.1259.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"2022062114102984000_48.8.1259.4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022062114102984000_48.8.1259.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2022062114102984000_48.8.1259.6","unstructured":"Otezla [package insert]. [Internet. Accessed April 29, 2021.] Available from: www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/otezla\/otezla_pi_english.ashx"},{"key":"2022062114102984000_48.8.1259.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00559.x"},{"key":"2022062114102984000_48.8.1259.8","doi-asserted-by":"crossref","first-page":"906349","DOI":"10.1155\/2015\/906349","article-title":"The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1)","volume":"2015","author":"Schafer","year":"2015","journal-title":"J Immunol Res"},{"key":"2022062114102984000_48.8.1259.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001"},{"key":"2022062114102984000_48.8.1259.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201915"},{"key":"2022062114102984000_48.8.1259.11","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2022062114102984000_48.8.1259.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2022062114102984000_48.8.1259.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2022062114102984000_48.8.1259.14","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2022062114102984000_48.8.1259.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2022062114102984000_48.8.1259.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.127"},{"key":"2022062114102984000_48.8.1259.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020503"},{"key":"2022062114102984000_48.8.1259.18","first-page":"862","article-title":"Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment","volume":"34","author":"Lukas","year":"2007","journal-title":"J Rheumatol"},{"key":"2022062114102984000_48.8.1259.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"2022062114102984000_48.8.1259.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.23901"},{"key":"2022062114102984000_48.8.1259.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.23471"},{"key":"2022062114102984000_48.8.1259.22","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794"},{"key":"2022062114102984000_48.8.1259.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140647"},{"key":"2022062114102984000_48.8.1259.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376"},{"key":"2022062114102984000_48.8.1259.25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology"},{"key":"2022062114102984000_48.8.1259.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"2022062114102984000_48.8.1259.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"2022062114102984000_48.8.1259.28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.201088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:20:09Z","timestamp":1655846409000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.201088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,1]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.3899\/jrheum.201088"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.201088","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}